Momentum investors typically don't time the market or "buy low and sell high." In other words, they avoid betting on cheap stocks and waiting long for them to recover. Instead, they believe that "buying high and selling higher" is the way to make far more money in lesser time.Who doesn't like betting on fast-moving trending stocks? But determining the right entry point isn't easy. Often, these stocks lose momentum once their valuation moves ahead of their future growth potential. In such a situation, invest ...

While "the trend is your friend" when it comes to short-term investing or trading, timing entries into the trend is a key determinant of success. And increasing the odds of success by making sure the sustainability of a trend isn't easy.The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the stock aliv ...

When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a trend to profit from it is easier said than done.Often, the direction of a stock's price movement reverses quickly after taking a position in it, making investors incur a short-term capital loss. So, it's important to ensure that there are enough factors -- such as sound fundamentals, positive earnings estimate rev ...

The assets of failed DNA testing firm 23andMe are being bought for $256 million. Biotechnology firm Regeneron Pharmaceuticals said on Monday it would acquire 23andMe's personal genome service, total health, and research services business lines, and its biobank of customers' genetic samples. Regeneron said San Francisco-headquartered 23andMe would continue to offer all consumer genome services. "We believe we can help 23andMe deliver and build upon its mission to help those interested in learning about th ...

EnglishItalianoEspañolPortuguêsDeutschالعربيةFrançaisImportant DisclaimersThe content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial decision, you should perform your ...

CenterPoint Energy Inc. (CNP) focuses on consistent investments in infrastructure upgrades and maintenance, which has played a critical role in the company's expanding operations. Given its strong growth, CNP makes for a solid investment option in the Zacks Utility Electric Power industry.Let us focus on the reasons that make this Zacks Rank #2 (Buy) stock a strong investment pick at the moment.CNP’s Growth ForecastThe Zacks Consensus Estimate for CNP’s 2025 earnings per share (EPS) stands at $1.75, which i ...

Veracyte’s (VCYT) shares have surged 30.9% in the past year, showing impressive momentum. It has significantly outperformed the industry’s 13.1% decline and the S&P 500 composite’s 12.1% gain.  Presently carrying a Zacks Rank #3 (Hold), the global diagnostics company continues to benefit from the robust performance of Afirma and Decipher tests. Their solid future growth potential, along with strategic investment in the long-term growth drivers, is highly promising.Based in San Francisco, CA, Veracyte offers ...

UnitedHealth Group Inc's UNH recent nosedive wasn't just a chart pattern — it was a conviction breaker. Tom Hulick, CEO of Strategy Asset Managers, didn't wait for a rebound. He dumped the stock, citing "a deterioration in fundamentals" in exclusive insights shared with Benizinga over email.UnitedHealth’s stock is down over 42% year-to-date, over 31% down in the past month alone.Asset Manager Walks Away From UNH StockThe asset manager's exit from UnitedHealth stock followed a string of gut punches for Unite ...

Archer Aviation Inc. (ACHR) recently released its first-quarter 2025 results. The company reported a loss of 13 cents per share, narrower than the Zacks Consensus Estimate of a loss of 21 cents. ACHR ended the first quarter with a robust cash position of $1.03 billion, which should ensure sufficient liquidity for the upcoming production and deployment phases of its Midnight Electric Vertical Take-Off and Landing (eVTOL) aircraft. The quarterly results also highlighted the company’s plans to deliver its firs ...

Wall Street analysts have issued a bearish outlook for UnitedHealth (NYSE: UNH) stock following a tumultuous week that saw the healthcare giant’s shares plummet 23%.Notably, the stock rebounded slightly after a flurry of high-profile insider buying signaled confidence. In pre-market trading on Monday, the stock rose 4% to $305.25, following a 6% gain in the previous session, which closed at $291.91.UNH one-day stock price chart. Source: Google FinanceThe sharp decline was triggered by a series of setbacks, ...